Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
To determine the effect of a special preparation of cells, called tumor-infiltrating
lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients
with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute